The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | A potential role for CAR-T therapy in patients with high-risk CLL
Patrick Derigs, MD, University Hospital Heidelberg, Heidelberg, Germany, talks on the potential role of chimeric antigen receptor T-cell (CAR-T) therapy in patients with chronic lymphocytic leukemia (CLL) with high-risk genetic abnormalities. Dr Derigs explains that in this difficult-to-treat patient population with few effective therapeutic options, CAR-T therapy represents a promising treatment strategy. However, there are still many concerns over the efficacy and durability of CAR-Ts in CLL. Third-generation retroviral vector-transduced CAR-Ts could help overcome these challenges. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
